Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

B- PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma

NCT04775550 is registered in ClinicalTrials.gov with Omar Nadeem, MD as lead sponsor.

NCT NCT04775550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04775550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
B- PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma
Lead sponsor
Omar Nadeem, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 8, 2021
Completion date
December 8, 2030
Enrollment
61 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk smoldering multiple myeloma, multiple myeloma